Answers are grounded in this paper and cite their sources.
Real-world evidence study reveals off-label use of therapies affects cardiovascular events in type 1 diabetes, suggesting important clinical implications.
A.P. has received grant funding (to the institution) from NHLBI, AHA, Roche, Ultromics, Astra Zeneca; has recieved honoraria outside of the present work as a consultant, advisor, or speaker from Tricog, Elli Lilly, Bayer, Astra Zeneca, Rivus, Roche, Axon Therapies, Novo Nrodisk, Merck, Abbott, Edwards Lifesciences, Anumana, MedicalAI, Science37, Kardigan, Antlia Biosciences, Kieele Health, Novartis, iRhythm, Sarfez Pharma, Boehringer Ingelheim, BSWRI, Tenax Pharma, Alnylam, and Vasa Theraputics. E.R. and C.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: